The Pharmaceutical Year in Review 2009 - Industry Trends and Lessons Learned
出 版 商：CBR Pharma Insights
出版日期：2009/12/15
頁 數：67頁
文件格式：PDF
價 格：
USD 3,900 (Single-User License)
USD 4,900 (Multi-User License)
USD 9,800 (Global-User License)
USD 4,900 (Multi-User License)
USD 9,800 (Global-User License)
The Pharmaceutical Year in Review 2009 - Industry Trends and Lessons Learned
Summary
2009 has been a turbulent year for the global economy and the increasing interconnectivity of business has amplified its impact on the pharmaceutical industry. As a result of the global recession, the pharmaceutical industry has seen a greater urgency to adapt its ways in order to continue to sustain any substantial growth.
Several key events & trends have been seen over the past year which will change the way the pharmaceutical industry looks going forward. Some of these include: the return of the “mega-merger”, healthcare reform in the United States, the Swine Flu pandemic, and impact of patent expires & generics.
CBR Pharma Insights’ report, “The Pharmaceutical Year in Review 2009 - Industry Trends and Lessons Learned” will help support your business planning initiatives as it identifies, reviews, and analyzes the major trends of 2009 and their impact on the pharmaceutical industry.
Scope
- Review of mergers, acquisitions and industry layoffs
- Analysis of pharmaceutical industry and their focus on emerging markets
- Overview of the generics industry in 2009
Reasons to buy
- Enhance your knowledge of the key trends and events that have helped to shape the pharmaceutical industry in 2009
- Understand the drivers behind recent M&A deals - large and small
- Identify the key product launches and patent expiries which will shape the pharmaceutical market going forward
- Gain insight into other industry players through extensive strategic case study analysis
- Learn how US healthcare reform is likely to shape your business
- Gain understanding of how the Swine Flu Pandemic is shaping companies results and pipelines
Summary
2009 has been a turbulent year for the global economy and the increasing interconnectivity of business has amplified its impact on the pharmaceutical industry. As a result of the global recession, the pharmaceutical industry has seen a greater urgency to adapt its ways in order to continue to sustain any substantial growth.
Several key events & trends have been seen over the past year which will change the way the pharmaceutical industry looks going forward. Some of these include: the return of the “mega-merger”, healthcare reform in the United States, the Swine Flu pandemic, and impact of patent expires & generics.
CBR Pharma Insights’ report, “The Pharmaceutical Year in Review 2009 - Industry Trends and Lessons Learned” will help support your business planning initiatives as it identifies, reviews, and analyzes the major trends of 2009 and their impact on the pharmaceutical industry.
Scope
- Review of mergers, acquisitions and industry layoffs
- Analysis of pharmaceutical industry and their focus on emerging markets
- Overview of the generics industry in 2009
Reasons to buy
- Enhance your knowledge of the key trends and events that have helped to shape the pharmaceutical industry in 2009
- Understand the drivers behind recent M&A deals - large and small
- Identify the key product launches and patent expiries which will shape the pharmaceutical market going forward
- Gain insight into other industry players through extensive strategic case study analysis
- Learn how US healthcare reform is likely to shape your business
- Gain understanding of how the Swine Flu Pandemic is shaping companies results and pipelines
Executive Summary
Mergers & Acquisitions
Top deals of 2009
Diversification
Case studies
Pharmaceutical industry layoffs
Main drivers
Key announcements
Case studies
Pharma turns to emerging markets for growth
Looking to EM’s to streamline functions
EM’s forecasted to drive strong growth
Case studies
Generics industry in 2009
Key 2009 influences
Major patent expires in 2009
Usage continues to rise
Patent settlements under scrutiny in US & EU
Pfizer’s Greenstone
Actavis & Ratiopharm up for sale
Pharma looks to biotech for future growth
Why emulate biotech
Case studies/examples – BMS, Eli Lilly, Merck, J&J
Pharma VC arms and the economic downturn
US Healthcare Reform nears reality
A timeline review
Proposed key impact points to US healthcare reform
Reform triggered by the ARRA
Impact on pharma
Impact of Swine flu
An introduction
Key companies
Vaccines see a boost
Flu antivirals
The GSK case study
New drug approvals in 2009
2004-2009 totals
NME’s & BLA’s approved by the FDA
Analysis by therapy area & company
New sales from existing drugs
Appendix
Mergers & Acquisitions
Top deals of 2009
Diversification
Case studies
Pharmaceutical industry layoffs
Main drivers
Key announcements
Case studies
Pharma turns to emerging markets for growth
Looking to EM’s to streamline functions
EM’s forecasted to drive strong growth
Case studies
Generics industry in 2009
Key 2009 influences
Major patent expires in 2009
Usage continues to rise
Patent settlements under scrutiny in US & EU
Pfizer’s Greenstone
Actavis & Ratiopharm up for sale
Pharma looks to biotech for future growth
Why emulate biotech
Case studies/examples – BMS, Eli Lilly, Merck, J&J
Pharma VC arms and the economic downturn
US Healthcare Reform nears reality
A timeline review
Proposed key impact points to US healthcare reform
Reform triggered by the ARRA
Impact on pharma
Impact of Swine flu
An introduction
Key companies
Vaccines see a boost
Flu antivirals
The GSK case study
New drug approvals in 2009
2004-2009 totals
NME’s & BLA’s approved by the FDA
Analysis by therapy area & company
New sales from existing drugs
Appendix
